

HEMATOLOGY AND ONCOLOGY FOR USMLE

IMPORTANT PATHOLOGIES

Leukopenias | Heme | Porphyrrias | Lead and Iron Poisoning
| Coagulation Disorders | Platelet Disorders | Thrombotic
Microangiopathies | Mixed Platelet and Coagulation
Disorders | Hereditary Thromophilias | Blood Transfusion
| Acute and Chronic Leukemias

LEUKOPENIAS

Leukopenia refers to a decrease in total white blood cell (WBC) count, predisposing the patient to infections. It is classified based on which WBC lineage is reduced.

I. Neutropenia

Definition

- Absolute neutrophil count (ANC) < 1500 cells/mm³
- Severe neutropenia: ANC < 500 cells/mm³ → high risk of life-threatening infections ⚠️

Why neutrophils matter

- Neutrophils are the first line of defense against bacterial and fungal infections.
- Severe neutropenia commonly presents with sepsis and recurrent infections 🦠

Causes

- Sepsis / post-infection: consumption and exhaustion of neutrophils
- Drugs: especially chemotherapy, antithyroid drugs, antibiotics
- Aplastic anemia: bone marrow failure → ↓ production
- Autoimmune diseases: e.g., SLE
- Radiation exposure: marrow suppression

- Congenital neutropenia: inherited defects in neutrophil production
-

2. Lymphopenia

Definition

- Absolute lymphocyte count $< 1500 \text{ cells/mm}^3$
- Children: $< 3000 \text{ cells/mm}^3$ (higher normal baseline)

Why lymphocytes matter

- Lymphocytes are crucial for adaptive immunity (T cells, B cells, NK cells).
- Lymphopenia leads to viral, fungal, and opportunistic infections 

Causes

- HIV infection: destruction of CD4^+ T cells
- Congenital immunodeficiencies:
 - DiGeorge syndrome (thymic aplasia)

- SCID (combined B and T cell deficiency)
 - Autoimmune disorders: e.g., SLE
 - Glucocorticoid therapy
 - Radiation
 - Sepsis and postoperative stress
-

3. Eosinopenia

Definition

- Absolute eosinophil count $< 30 \text{ cells/mm}^3$

Causes

- Cushing syndrome
- Exogenous glucocorticoids

Eosinopenia itself is usually clinically insignificant, but it helps indicate steroid excess 

Effect of Glucocorticoids on WBCs ⚡

- Cause neutrophilia, despite causing leukopenia of other cells
- Mechanism:
 - ↓ activation of neutrophil adhesion molecules
 - Neutrophils remain in circulation instead of migrating to tissues
- Cause lymphopenia:
 - Induce apoptosis of lymphocytes
- Cause eosinopenia:
 - Sequestration in lymph nodes

 Key concept:

Glucocorticoids increase neutrophils in blood but impair immune function overall

HEME SYNTHESIS, PORPHYRIAS & LEAD POISONING

Porphyrias are disorders of defective heme synthesis, leading to accumulation of toxic heme precursors.

Lead poisoning mimics porphyrias by inhibiting key enzymes 

1. Lead Poisoning

Affected Enzymes

- ALA dehydratase
- Ferrochelatase

Accumulated Substrates

- δ -Aminolevulinic acid (ALA)
- Protoporphyrin

Hematologic Findings

- Microcytic anemia
- Basophilic stippling on peripheral smear
- Ringed sideroblasts in bone marrow 

Clinical Features

- GI symptoms: abdominal pain

- Renal disease
 - Children: lead paint exposure → neurodevelopmental delay
 - Adults: batteries, ammunition → headache, memory loss, peripheral neuropathy
-

2. Acute Intermittent Porphyria (AIP)

Enzyme Defect

- Porphobilinogen deaminase
- Autosomal dominant

Accumulated Substrates

- Porphobilinogen
- ALA

Classic Symptoms - "S P's"

1. Painful abdomen
2. Port wine-colored urine

3. Polyneuropathy

4. Psychological disturbances

5. Precipitated by \uparrow ALA synthase

Triggers

- CYP450-inducing drugs
- Alcohol
- Starvation

Treatment

- Hemin
- Glucose (\downarrow ALA synthase activity)

 Important:

No photosensitivity in AIP  

3. Porphyria Cutanea Tarda (PCT)

Enzyme Defect

- Uroporphyrinogen decarboxylase

Accumulated Substrate

- Uroporphyrin → tea-colored urine ☕

Clinical Features

- Blistering photosensitivity
- Hyperpigmentation
- Most common porphyria

Exacerbating Factors

- Alcohol
- Hepatitis C

Treatment

- Phlebotomy
- Sun avoidance
- Antimalarials (e.g., hydroxychloroquine)

Heme Synthesis Pathway

- Succinyl-CoA + Glycine
 - ↓ (ALA synthase - rate-limiting step)
 - ALA
 - ↓ (ALA dehydratase - inhibited by lead)
 - Porphobilinogen
 - ↓ (Porphobilinogen deaminase - AIP)
 - Hydroxymethylbilane
 - ↓
 - Uroporphyrinogen III
 - ↓ (Uroporphyrinogen decarboxylase - PCT)
 - Protoporphyrin
 - ↓ (Ferrochelatase - inhibited by lead)
 - Heme (Fe^{2+} added) 
-

IRON POISONING

Iron poisoning can present as acute (usually accidental) or chronic (due to iron overload states).

1. Acute Iron Poisoning

Key Findings

- High mortality rate, especially in children
- Occurs due to accidental ingestion of iron tablets
- Adult iron tablets may look like candy 🍬 →
common cause in pediatrics

Mechanism

- Excess iron causes free radical formation
- Leads to lipid peroxidation of cell membranes
- Result: direct cellular injury and cell death ⚠️

Symptoms and Signs

- Severe abdominal pain
- Vomiting
- GI bleeding
- Radiopaque iron pills visible on abdominal X-ray 📷
- May progress to:

- Anion gap metabolic acidosis
- Multiorgan failure
- Late complication:
 - GI scarring → intestinal obstruction

Treatment

- Chelation therapy
 - Deferoxamine
 - Deferasirox
- Gastric lavage (early cases)

 Exam pearl:

Acute iron poisoning = GI symptoms + metabolic acidosis + radiopaque pills

2. Chronic Iron Poisoning (Iron Overload)

Seen In

- Primary (hereditary) hemochromatosis
- Secondary hemochromatosis, e.g.:

- Chronic blood transfusions (thalassemia, sickle cell disease)

Mechanism

- Progressive iron deposition in tissues
- Causes organ dysfunction due to oxidative damage

Symptoms and Signs

- Arthropathy
- Cirrhosis of liver
- Cardiomyopathy
- Diabetes mellitus
- Skin hyperpigmentation
 - Classic: "Bronze diabetes" ●
- Hypogonadism

Treatment

- Phlebotomy (if patient is not anemic)
- Chelation therapy (if phlebotomy not possible)

COAGULATION DISORDERS - BASIC TESTS

1. Prothrombin Time (PT)

What it Tests

- Extrinsic pathway + common pathway
- Factors: I, II, V, VII, X

Key Point

- Defect → ↑ PT

 Mnemonic:

"Play Tennis Outside" → Extrinsic pathway 

2. INR (International Normalized Ratio)

- $INR = \text{Patient PT} / \text{Control PT}$
- Normal INR = 1
- $INR > 1 \rightarrow$ prolonged clotting

Clinical Use

- Most common test to monitor warfarin therapy
 - Warfarin → ↑ INR
-

3. Partial Thromboplastin Time (PTT)

What it Tests

- Intrinsic pathway + common pathway
- Tests all factors except VII and XIII

Key Point

- Defect → ↑ PTT

 Mnemonic:

“Play Table Tennis Inside” 

4. Thrombin Time (TT)

What it Measures

- Conversion of fibrinogen → fibrin

Prolonged In

- Anticoagulant therapy
 - Hypofibrinogenemia
 - DIC
 - Liver disease
-

MIXING STUDY

Used to differentiate between:

- Clotting factor deficiency
- Factor inhibitor

How it Works

- Normal plasma is mixed with patient plasma

Interpretation

- Correction of PT/PTT → Factor deficiency

- No correction → Factor inhibitor
 - Most commonly anti-factor VIII
-

SPECIFIC COAGULATION DISORDERS

Hemophilia A, B, and C

PT / PTT Pattern

- PT: Normal
- PTT: Increased

Mechanism

- Intrinsic pathway defect

Types

- Hemophilia A
 - Factor VIII deficiency
 - X-linked recessive
 - Pronounced: "hemophilia ate (eight)" 🗿
- Hemophilia B

- Factor IX deficiency
- X-linked recessive
- Hemophilia C
 - Factor XI deficiency
 - Autosomal recessive

Clinical Features

- Hemarthroses (bleeding into joints, esp. knee)
- Easy bruising
- Excessive bleeding after trauma or surgery (e.g., dental extraction) 

Treatment

- Hemophilia A
 - Desmopressin
 - Factor VIII concentrate
 - Emicizumab
- Hemophilia B
 - Factor IX concentrate
- Hemophilia C

- Factor XI concentrate
-

Vitamin K Deficiency

PT / PTT Pattern

- ↑ PT
- ↑ PTT
- Bleeding time: Normal

Mechanism

- ↓ activity of vitamin K-dependent factors
 - II, VII, IX, X
 - Protein C and Protein S

 Key exam line:

Vitamin K deficiency affects both intrinsic and extrinsic pathways

PLATELET DISORDERS – GENERAL FEATURES

All platelet disorders share some core clinical features:

- ↑ Bleeding time (BT) 
- Mucocutaneous bleeding
 - Epistaxis
 - Gum bleeding
 - Menorrhagia
- Microhemorrhages
 - Petechiae
 - Purpura

Platelet Count (PC)

- Usually decreased
- May be normal in qualitative platelet disorders (function defect, not number)

 Key concept:

Platelet disorders → bleeding from skin & mucous membranes, not deep muscle bleeds

SPECIFIC PLATELET DISORDERS

1. Bernard-Soulier Syndrome

Platelet Count / Bleeding Time

- Platelet count: ↓ or normal
- Bleeding time: ↑

Pathophysiology

- Autosomal recessive
- Defect in platelet adhesion
- ↓ GpIb receptor
 - Normally binds vWF
 - Required for platelet adhesion to damaged endothelium

→ Result: Impaired platelet-vWF adhesion

Laboratory Findings

- Decreased platelet aggregation

- Giant (big) platelets on blood smear 

 One-liner:

Bernard-Soulier = GpIb defect → adhesion problem

2. Glanzmann Thrombasthenia

Platelet Count / Bleeding Time

- Platelet count: ↓ or normal
- Bleeding time: ↑

Pathophysiology

- Autosomal recessive
- Defect in platelet aggregation
- ↓ GpIIb/IIIa (integrin α IIb β 3)

 Platelets cannot bind fibrinogen

 Platelet-to-platelet aggregation fails 

Laboratory Findings

- Blood smear shows no platelet clumping

 One-liner:

Glanzmann = GpIIb/IIIa defect → aggregation problem

3. Immune Thrombocytopenia (ITP)

Platelet Count / Bleeding Time

- Platelet count: ↓
- Bleeding time: ↑

Pathophysiology

- Autoimmune destruction of platelets
- Anti-GpIIb/IIIa antibodies
- Antibody-coated platelets are phagocytosed by splenic macrophages 

Causes

- Idiopathic

- Secondary to:
 - Autoimmune diseases (e.g., SLE)
 - Viral infections (HIV, HCV)
 - Malignancies (e.g., CLL)
 - Drug reactions

Laboratory Findings

- ↓ Platelet count
- ↑ Megakaryocytes in bone marrow (compensatory response)

Treatment

- First line: Glucocorticoids
- Others:
 - IVIG
 - Rituximab
 - TPO receptor agonists (eltrombopag, romiplostim)
- Refractory cases: Splenectomy 

 Exam pearl:

ITP = low platelets + increased megakaryocytes

4. Uremic Platelet Dysfunction

Platelet Count / Bleeding Time

- Platelet count: Normal
- Bleeding time: ↑

Mechanism

- Occurs in chronic renal failure
- Accumulation of uremic toxins
- Toxins interfere with platelet adhesion and aggregation

 Important:

Platelet number is normal, but function is impaired

THROMBOTIC MICROANGIOPATHIES (TMA)

These disorders:

- Share overlapping features
- Can resemble DIC
- DO NOT show consumptive coagulopathy

Key Difference from DIC

- Normal PT and PTT
 - Normal fibrinogen
 - Clotting cascade is not activated ⚠
-

THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)

Epidemiology

- Typically adult females

Pathophysiology

- Deficiency or inhibition of ADAMTS13

- ADAMTS13 = vWF metalloprotease
 - ↓ cleavage of large vWF multimers
 - Accumulation of large vWF multimers
 - → Excessive platelet adhesion and aggregation
 - → Microthrombi formation
-

HEMOLYTIC UREMIC SYNDROME (HUS)

Epidemiology

- Typically children

Pathophysiology

- Most commonly caused by Shiga toxin-producing E. coli
 - Serotype O157:H7
 - Toxin causes severe endothelial damage
 - Leads to platelet activation and microthrombi
-

COMMON PRESENTATION (Triad) – TTP & HUS

Classic Triad

1. Thrombocytopenia (↓ platelets)
 2. Microangiopathic hemolytic anemia
 - ↓ Hemoglobin
 - Schistocytes on smear
 - ↑ LDH
 3. Acute kidney injury
 - ↑ Creatinine
-

Differentiating Features

Feature	TTP	HUS
Additional symptoms	Fever + neurologic symptoms 	Bloody diarrhea
PT / PTT	Normal	Normal

 Key exam line:

Normal PT & PTT help distinguish TTP/HUS from DIC

Treatment

TTP

- Plasma exchange (treatment of choice)
- Glucocorticoids
- Rituximab

HUS

- Supportive care only
 - Fluids
 - Dialysis if needed
-

MIXED PLATELET AND COAGULATION DISORDERS

These disorders affect both primary hemostasis (platelets) and secondary hemostasis (coagulation cascade).

Hence, abnormalities are seen in bleeding time (BT) and sometimes PT / PTT.

VON WILLEBRAND DISEASE (vWD)

Platelet Count / Bleeding Time / PT / PTT

- Platelet count: Normal
 - Bleeding time: ↑
 - PT: Normal
 - PTT: Normal or ↑
-

Pathophysiology (Two Key Defects ⚠)

1. Platelet Plug Formation Defect

- ↓ von Willebrand factor (vWF)

- vWF is needed for platelet adhesion to exposed collagen via GpIb
- Result → defective platelet-vWF adhesion 

2. Intrinsic Pathway Coagulation Defect

- vWF carries and protects factor VIII
- ↓ vWF → ↓ factor VIII
- Result → ↑ PTT

 Key concept:

vWD affects both platelets and coagulation

Genetics

- Most common inherited bleeding disorder
 - Usually autosomal dominant
 - Generally mild
-

Clinical Presentation

- Menorrhagia
 - Epistaxis
 - Easy bruising
 - Mucocutaneous bleeding
-

Treatment

- Desmopressin
 - Releases vWF stored in endothelial cells
 - vWF-containing factor VIII concentrates
-

DISSEMINATED INTRAVASCULAR COAGULATION (DIC)

A consumptive coagulopathy caused by widespread activation of the coagulation cascade.

Platelet Count / Bleeding Time / PT / PTT

- Platelet count: ↓

- Bleeding time: ↑
 - PT: ↑
 - PTT: ↑
-

Pathophysiology

- Systemic activation of clotting factors → microthrombi formation
- Rapid consumption of:
 - Platelets
 - Clotting factors
- Leads to simultaneous thrombosis and bleeding ⚠️

 Classic description:

“Clot everywhere, bleed everywhere”

Clinical Features

- Thromboses
- Hemorrhages

- Oozing from IV lines or puncture sites
 - May be:
 - Acute (life-threatening)
 - Chronic (if liver compensates)
-

Causes - SSSTOP

- Sepsis (especially gram-negative)
 - Snake bites
 - Stroke (heat stroke)
 - Trauma
 - Obstetric complications
 - Pancreatitis (acute)
 - Also: malignancy, nephrotic syndrome, massive transfusion
-

Laboratory Findings

- Schistocytes on blood smear

- ↑ D-dimers (fibrin degradation products)
 - ↓ Fibrinogen
 - ↓ Factors V and VIII
-

HEREDITARY THROMBOPHILIAS

These are autosomal dominant disorders causing a hypercoagulable state, i.e., ↑ tendency to form clots 

I. Antithrombin Deficiency

Mechanism

- Antithrombin normally inhibits:
 - Factor IIa (thrombin)
 - Factor Xa
- Deficiency → excess clot formation

Lab

- PT, PTT, TT: Normal

- Heparin resistance
 - Heparin works by activating antithrombin
 - Deficiency → ↓ rise in PTT after heparin

Acquired Causes

- Nephrotic syndrome / renal failure
 - Loss of antithrombin in urine 
-

2. Factor V Leiden Mutation

Mechanism

- Point mutation: Arg506Gln
- Factor V becomes resistant to activated protein C
- Failure to inactivate Va

Clinical Complications

- Deep vein thrombosis (DVT)
- Cerebral vein thrombosis
- Recurrent pregnancy loss

 Most common inherited thrombophilia

3. Protein C or Protein S Deficiency

Mechanism

- Normally:
 - Protein C cancels
 - Protein S stops coagulation 
- Deficiency → ↓ inactivation of factors Va and VIIIa

Clinical Significance

- Hypercoagulable state
 - ↑ risk of warfarin-induced skin necrosis
 - Due to early loss of protein C (short half-life)
-

4. Prothrombin G20210A Mutation

Mechanism

- Point mutation in 3' untranslated region

- Leads to ↑ prothrombin production
- ↑ plasma prothrombin → ↑ clot risk

Clinical Feature

- Venous thrombosis
-

Summary Line

vWD = platelet + intrinsic pathway defect

DIC = consumption of platelets and clotting factors

Thrombophilias = normal labs, abnormal clotting tendency

BLOOD TRANSFUSION THERAPY

Blood transfusion is used to restore oxygen-carrying capacity, hemostasis, or intravascular volume, depending on the component transfused.

1. Packed Red Blood Cells (PRBCs)

Dose & Effect

- ↑ Hemoglobin ~1 g/dL per unit
- ↑ Hematocrit ~3% per unit
- Improves oxygen-carrying capacity 

Clinical Uses

- Acute blood loss
- Severe or symptomatic anemia

 Key point:

PRBCs are preferred over whole blood to avoid volume overload.

2. Platelets

Dose & Effect

- ↑ Platelet count ~30,000/ μ L per unit
 - (\approx ↑ 5,000/ mm^3 per unit)

Clinical Uses

- Active or significant bleeding
- Thrombocytopenia
- Qualitative platelet defects

 Exam tip:

Platelets are given based on bleeding risk, not just platelet number.

3. Fresh Frozen Plasma (FFP) / Prothrombin Complex Concentrate (PCC)

Contents

- FFP
 - All coagulation factors
 - Plasma proteins
- PCC
 - Factors II, VII, IX, X
 - Proteins C and S

Effect

- ↑ Coagulation factor levels

Clinical Uses

- Cirrhosis
- Immediate reversal of anticoagulation (especially warfarin)

 High-yield:

PCC acts faster and requires less volume than FFP



4. Cryoprecipitate

Contents

- Fibrinogen
- Factor VIII
- Factor XIII
- von Willebrand factor

- Fibronectin

Clinical Uses

- Hypofibrinogenemia
- Factor VIII deficiency
- Certain bleeding disorders

 Mnemonic:

Cryo = "F8, F13, vWF, fibrinogen"

S. Albumin

Effect

- ↑ Intravascular volume
- ↑ Oncotic pressure

Clinical Uses

- Post-paracentesis
- Therapeutic plasmapheresis

RISKS OF BLOOD TRANSFUSION ⚠️

Although generally safe, transfusions carry important risks:

- Infection transmission (very low risk)
- Transfusion reactions
- TACO (Transfusion-Associated Circulatory Overload)
 - Volume overload → pulmonary edema, hypertension
- TRALI (Transfusion-Related Acute Lung Injury)
 - Hypoxia + inflammation
 - Noncardiogenic pulmonary edema
 - Hypotension
- Iron overload
 - Chronic transfusions → secondary hemochromatosis
- Hypocalcemia
 - Citrate chelates Ca^{2+}

- Hyperkalemia
 - RBC lysis in stored blood 
-

LEUKEMIA vs LYMPHOMA

Leukemia

- Myeloid or lymphoid neoplasm
- Diffuse bone marrow involvement
- Tumor cells commonly found in peripheral blood

Lymphoma

- Discrete solid tumor
 - Arises from lymph nodes
 - May have:
 - Extranodal involvement
 - Leukemic presentation
-

HODGKIN vs NON-HODGKIN LYMPHOMA

Shared Features

- May have B symptoms:
 - Low-grade fever
 - Night sweats 🌙
 - Weight loss
-

Hodgkin Lymphoma

- Localized
- Single lymph node group
- Contiguous spread
- Stage = strongest prognostic factor
- Better prognosis overall
- Characterized by Reed-Sternberg cells
- Mostly B-cell origin
- Bimodal age distribution
 - Young adults
 - 55 years
- Associated with EBV

- May be associated with autoimmune diseases
-

Non-Hodgkin Lymphoma

- Multiple lymph nodes involved
 - Noncontiguous spread
 - Extranodal involvement common
 - Worse prognosis
 - May arise from B or T cells
 - Associated with:
 - HIV
 - EBV
 - HTLV
-

LEUKEMIAS

Definition

- Malignant disorders with unregulated proliferation of WBCs in bone marrow

- → Marrow failure, causing:
 - Anemia (↓ RBCs)
 - Infections (↓ functional mature WBCs)
 - Hemorrhage (↓ platelets)

Peripheral blood

- Usually ↑ circulating WBCs (malignant leukocytes)
- Sometimes normal or ↓ WBC count

Organ infiltration

- Liver
- Spleen
- Lymph nodes
- Skin → Leukemia cutis

LYMPHOID NEOPLASMS

ACUTE LYMPHOBLASTIC LEUKEMIA / LYMPHOMA (ALL)

Epidemiology

- Most common childhood leukemia
- Less common in adults → worse prognosis
- Associated with Down syndrome

Clinical features

- T-cell ALL → mediastinal mass
 - May cause SVC-like syndrome
- May spread to:
 - CNS
 - Testes

Peripheral blood & bone marrow

- ↑ ↑ ↑ lymphoblasts

Immunophenotype

- TdT+ (marker of pre-B & pre-T cells)
- CD10+ (pre-B cell marker)

Genetics & prognosis

- t(12;21) → good prognosis
- t(9;22) (Philadelphia chromosome) → poor prognosis

Treatment response

- Most responsive leukemia to therapy
-

CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

Epidemiology

- Age >60 years
- Most common adult leukemia

Cell type & markers

- Mature B-cell neoplasm
- CD20+, CD23+, CD5+

Clinical features

- Often asymptomatic
- Slow progression
- Autoimmune hemolytic anemia

Peripheral smear

- Smudge cells
- Mnemonic: CLL = Crushed Little Lymphocytes

Complication

- Richter transformation
 - CLL/SLL → Diffuse large B-cell lymphoma (DLBCL)

HAIRY CELL LEUKEMIA

Epidemiology

- Adult males
- Mature B-cell tumor

Morphology

- Cells with hair-like cytoplasmic projections
- "Fuzzy" appearance on LM
- Peripheral lymphadenopathy uncommon

Bone marrow

- Marrow fibrosis
- → Dry tap on aspiration

Clinical features

- Massive splenomegaly
- Pancytopenia

Stains & genetics

- TRAP positive
 - (TRAPped in a hairy situation)
- TRAP largely replaced by flow cytometry
- Associated with BRAF mutation

Treatment

- Purine analogs
 - Cladribine
 - Pentostatin
-

MYELOID NEOPLASMS

ACUTE MYELOGENOUS LEUKEMIA (AML)

Epidemiology

- Median age ~65 years

Peripheral smear

- ↑ ↑ ↑ myeloblasts
- Auer rods
- Myeloperoxidase positive

Special subtype — APL (M3 AML)

- Promyelocytes
- t(15;17) → PML-RAR α
- High risk of DIC
- Treatment:
 - All-trans retinoic acid (ATRA)
 - Arsenic trioxide
 - → induces differentiation

Clinical complication

- Leukostasis
 - Capillary occlusion by rigid malignant cells
 - → organ damage

Risk factors

- Alkylating chemotherapy
 - Radiation
 - Benzene exposure
 - Myeloproliferative disorders
 - Down syndrome
 - Typically acute megakaryoblastic leukemia (M7)
-

CHRONIC MYELOGENOUS LEUKEMIA (CML)

Epidemiology

- Peak: 45-85 years
- Median age: 64 years

Genetics

- Philadelphia chromosome
- $t(9;22) \rightarrow$ BCR-ABL

Pathophysiology

- Myeloid stem cell proliferation
- Dysregulated production of:
 - Neutrophils
 - Myelocytes
 - Metamyelocytes
 - Basophils

Clinical features

- Splenomegaly
- Fatigue, weight loss

Disease course

- May progress to:
 - AML
 - ALL

- → called blast crisis

Treatment

- BCR-ABL tyrosine kinase inhibitors
 - Imatinib

LEUKEMOID REACTION VS CHRONIC MYELOGENOUS LEUKEMIA (CML)

Feature	Leukemoid Reaction	CML
Definition	Reactive neutrophilia ($>50,000$ cells/mm ³)	Clonal myeloproliferative neoplasm
Neutrophil morphology	Toxic granulation, Döhle bodies, cytoplasmic vacuoles	Pseudo-Pelger-Huët anomaly
LAP score	↑ (high)	↓ (low; LAP enzyme ↓ in malignant neutrophils)

Basophils & eosinophils	Normal	↑
-------------------------	--------	---

Notes / Mnemonics

- PV & ET → JAK2 mutation common
 - Myelofibrosis → "Bone marrow cries" = fibrosis + dry tap
 - Leukemoid reaction → reactive, LAP ↑
 - CML → BCR-ABL + LAP ↓, basophilia characteristic
-

-> The End <-